RIO DE JANEIRO, BRAZIL - The Covid-19 vaccine under development at Oxford University in the UK is entering its third round of clinical trials this week, in which at least 10,000 people will be vaccinated across the country to determine its effectiveness.
Among the over 70 immunizing agents currently under development worldwide, this is considered the most advanced and also the most promising. Leading the trial at the Liverpool School of Tropical Medicine is a 37-year-old Brazilian immunologist, Daniela Ferreira, who specializes in respiratory infections and vaccine development.
The focus on this immunizing agent is such that . . .